(Q37866779)

24 August 2017

1 reference

title

Cetuximab in the treatment of squamous cell carcinoma of the head and neck (English)

1 reference

24 August 2017

1 reference

squamous cell carcinoma

1 reference

Pol Specenier

1

1 reference

24 August 2017

Jan B Vermorken

series ordinal

2

1 reference

24 August 2017

publication date

1 April 2011

1 reference

Expert Review of Anticancer Therapy

24 August 2017

published in

1 reference

24 August 2017

volume

11

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

511-524

1 reference

Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma?

24 August 2017

cites work

1 reference

HPV-associated head and neck cancer: a virus-related cancer epidemic

21 January 2018

1 reference

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

21 January 2018

1 reference

Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro.

21 January 2018

1 reference

Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck.

21 January 2018

1 reference

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

21 January 2018

1 reference

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

21 January 2018

1 reference

Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.

21 January 2018

1 reference

Severe cutaneous toxicity following treatment with radiotherapy and cetuximab: a case report

21 January 2018

1 reference

Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab

21 January 2018

1 reference

High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes

21 January 2018

1 reference

Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer.

21 January 2018

1 reference

Severe cutaneous reaction to cetuximab with possible association with the use of over-the-counter skin care products in a patient with oropharyngeal cancer.

21 January 2018

1 reference

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients

21 January 2018

1 reference

Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck.

21 January 2018

1 reference

Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer

21 January 2018

1 reference

Radiochemotherapy with cetuximab, cisplatin, and amifostine for locally advanced head and neck cancer: a feasibility study

21 January 2018

1 reference

Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer

21 January 2018

1 reference

Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.

21 January 2018

1 reference

Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck

21 January 2018

1 reference

Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

21 January 2018

1 reference

Neoadjuvant chemotherapy in head and neck cancer: should it be revisited?

21 January 2018

1 reference

Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation

21 January 2018

1 reference

Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer

21 January 2018

1 reference

Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer

21 January 2018

1 reference

Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck

21 January 2018

1 reference

Active surveillance for prostate cancer: has the time finally come?

21 January 2018

1 reference

Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial

21 January 2018

1 reference

Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape

21 January 2018

1 reference

Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer

21 January 2018

1 reference

Combined cetuximab and reirradiation for locoregional recurrent and inoperable squamous cell carcinoma of the head and neck.

21 January 2018

1 reference

Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head

21 January 2018

1 reference

Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck

21 January 2018

1 reference

Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

Platinum-based chemotherapy plus cetuximab in head and neck cancer

21 January 2018

1 reference

Optimal treatment for recurrent/metastatic head and neck cancer.

21 January 2018

1 reference

Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01.

21 January 2018

1 reference

An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom.

21 January 2018

1 reference

Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal

21 January 2018

1 reference

Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors

21 January 2018

1 reference

The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies

21 January 2018

1 reference

Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors.

21 January 2018

1 reference

Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck

21 January 2018

1 reference

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.11.20

1 reference

24 August 2017

1 reference